A treatment combined prussian blue nanoparticles with low-intensity pulsed ultrasound alleviates cartilage damage in knee osteoarthritis by initiating PI3K/Akt/mTOR pathway

被引:1
|
作者
Zuo, Deyu [1 ]
Tan, Botao [1 ]
Jia, Gongwei [1 ]
Wu, Dandong [1 ]
Yu, Lehua [1 ]
Jia, Lang [1 ]
机构
[1] Chongqing Med Univ, Affiliated Hosp 2, Dept Rehabil Med, Chongqing 400010, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
Osteoarthritis (OA); prussian blue nanoparticles (PBNPs); low-intensity pulsed ultrasound (LIPUS); CHONDROCYTE APOPTOSIS; MESENCHYMAL STEM; GENE-EXPRESSION; COLLAGENASE; II COLLAGEN; OXYGEN; DEGRADATION; INDUCTION; INTERLEUKIN-1-BETA; DIFFERENTIATION;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Reactive oxidative stress (ROS) related apoptosis in chondrocytes and extracellular matrix (ECM) degradation play crucial roles in the process of osteoarthritis. Prussian blue nanoparticles are known to scavenge ROS in cellular. Low-intensity pulsed ultrasound has been used as a non-invasive modality for the is widely used in clinical rehabilitation management of OA. In this study, we aim to investigate the effects of PBNPs/LIPUS combined treatment on knee osteoarthritis (KOA) and to determine whether phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway mediates this process. Use LPS to process primary cells of knee joint cartilage to establish a cartilage knee arthritis model. After treated with LIPUS and PBNPs, cell viability was rated by CCK-8 and ROS levels were assessed by DCFH-DA. Articular pathological changes were observed by naked eyes, H&E, and Safranin O staining, then monitored by cartilage lesion grades and Mankin's score. Cellular ROS, apoptosis rate, and TUNEL staining of chondrocytes were fairly decreased in the PBNPs group and the LIPUS group but drastically down-regulated in the PBNPs/LIPUS combination treatment group when compared with the LPS group. Western blot results showed that the cleaved caspase-3, Bax, IL-1 beta, MMP3 and MMP13 in the PBNPs and LIPUS groups slightly decreased, and Bcl2 increased slightly, while in the combination treatment group, the former was significantly decreased, and Bcl2 was Significantly increased. The PBNPs/LIPUS combination treatment reduced cellular ROS, apoptosis, and matrix metalloproteinases (MMPs), as a consequence, alleviated articular cartilage damage in KOA. Moreover, the PBNPs/LIPUS combination treatment suppressed the JNK/c-Jun signal pathway.
引用
收藏
页码:3987 / 4006
页数:20
相关论文
共 39 条
  • [21] Low-intensity-pulsed-ultrasound-treated menstrual-blood-derived mesenchymal stem cells repair endometrial injury by PI3K/AKT pathway inhibition
    Huang, Shuangying
    Cheng, Chunxia
    Wang, Zhibiao
    Li, Ruizhen
    Li, Waixing
    Yu, Kenan
    Shi, Qiuling
    Xue, Min
    REPRODUCTIVE BIOMEDICINE ONLINE, 2025, 50 (03)
  • [22] Low Dose of 5-Aminolevulinic Acid Hydrochloride Alleviates the Damage in Cardiomyocytes Induced by Lenvatinib via PI3K/AKT Signaling Pathway
    Shi, Yun
    Hu, Fengying
    Fu, Hao
    Li, Shaojie
    Lu, Chengzhi
    Hu, Chunxiu
    DISCOVERY MEDICINE, 2023, 35 (177) : 483 - 491
  • [23] Low-Intensity Pulsed Ultrasound Treatment at an Early Osteoarthritis Stage Protects Rabbit Cartilage From Damage via the Integrin/Focal Adhesion Kinase/Mitogen-Activated Protein Kinase Signaling Pathway
    Xia, Peng
    Shen, Shihao
    Lin, Qiang
    Chen, Kai
    Ren, Shasha
    Gao, Mingxia
    Li, Xueping
    JOURNAL OF ULTRASOUND IN MEDICINE, 2015, 34 (11) : 1991 - 1999
  • [24] Low-dose testosterone alleviates vascular damage caused by castration in male rats in puberty via modulation of the PI3K/AKT signaling pathway
    Zhao, Jing
    Liu, Ge-Li
    Wei, Ying
    Jiang, Li-Hong
    Bao, Peng-Li
    Yang, Qing-Yan
    MOLECULAR MEDICINE REPORTS, 2016, 14 (03) : 2518 - 2526
  • [25] Low concentration of rutin treatment might alleviate the cardiotoxicity effect of pirarubicin on cardiomyocytes via activation of PI3K/AKT/mTOR signaling pathway
    Fei, Junjie
    Sun, Yi
    Duan, Yuyin
    Xia, Jianming
    Yu, Songhua
    Ouyang, Peigang
    Wang, Teng
    Zhang, Guimin
    BIOSCIENCE REPORTS, 2019, 39
  • [26] RETRACTED: GABARAP promotes bone marrow mesenchymal stem cells-based the osteoarthritis cartilage regeneration through the inhibition of PI3K/AKT/mTOR signaling pathway (Retracted Article)
    Wu, Zhengyuan
    Lu, Huiping
    Yao, Jun
    Zhang, Xiaohan
    Huang, Yimei
    Ma, Shiting
    Zou, Kai
    Wei, Yan
    Yang, Zhengyi
    Li, Jia
    Zhao, Jinmin
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (11) : 21014 - 21026
  • [27] Panax ginseng root aqueous extract mediated biosynthesis of silver nanoparticles under ultrasound condition and investigation of the treatment of human lung adenocarcinoma with following the PI3K/AKT/ mTOR signaling pathway
    He, Jihong
    Feizipour, Saba
    Veisi, Hojat
    Amraii, Sara Amirpour
    Zangeneh, Mohammad Mahdi
    Hemmati, Saba
    INORGANIC CHEMISTRY COMMUNICATIONS, 2024, 160
  • [28] Low-intensity low-frequency ultrasound enhances the chemosensitivity of gemcitabine-resistant ASPC-1 cells via PI3K/AKT/NF-κB pathway-mediated ABC transporters
    Qiu, Fuqiang
    Chen, Jifan
    Cao, Jing
    Diao, Feng
    Huang, Pintong
    ONCOLOGY REPORTS, 2020, 44 (03) : 1158 - 1168
  • [29] Traditional Chinese Manual Therapy (Tuina) Improves Knee Osteoarthritis by Regulating Chondrocyte Autophagy and Apoptosis via the PI3K/AKT/mTOR Pathway: An in vivo Rat Experiment and Machine Learning Study
    Wang, Zhen
    Xu, Hui
    Wang, Zheng
    Wang, Yu
    Diao, Jieyao
    Chen, Juntao
    Xie, Yuchen
    Zhang, Lijuan
    Li, Miaoxiu
    Bian, Yanqin
    Zhou, Yunfeng
    JOURNAL OF INFLAMMATION RESEARCH, 2024, 17 : 6501 - 6519
  • [30] Inetetamab combined with sirolimus and chemotherapy for the treatment of HER2-positive metastatic breast cancer patients with abnormal activation of the PI3K/Akt/mTOR pathway after trastuzumab treatment
    Li, Qiao
    Lv, Dan
    Sun, Xiaoying
    Wang, Mengyuan
    Cai, Li
    Liu, Feng
    Li, Chenghui
    Zhao, Jiuda
    Sun, Jing
    Shi, Yehui
    Ma, Fei
    CANCER INNOVATION, 2024, 3 (05):